Scarica l'app Stockscreener
0.74
1.32%
-0.0099
Dopo l'orario di chiusura:
.72
-0.02
-2.70%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Perché IBIO Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.7499
Aprire:
$0.754
Volume 24 ore:
937.17K
Relative Volume:
0.88
Capitalizzazione di mercato:
$15.69M
Reddito:
$2.05M
Utile/perdita netta:
$-23.15M
Rapporto P/E:
-0.1116
EPS:
-6.6319
Flusso di cassa netto:
$-16.93M
1 W Prestazione:
+1.37%
1M Prestazione:
-9.87%
6M Prestazione:
-69.42%
1 anno Prestazione:
-62.05%
Intervallo 1D:
$0.7108
$0.754
Intervallo di 1 settimana:
$0.68
$0.81
Portata 52W:
$0.6358
$6.8908
iBio Inc Stock (IBIO) Company Profile
Nome
iBio Inc
Settore
Industria
Telefono
302-355-0650
Indirizzo
600 Madison Avenue, Suite 1601, New York, NY
Confronta IBIO con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IBIO
iBio Inc
|
0.74 | 15.69M | 2.05M | -23.15M | -16.93M | -6.6319 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.03 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.74 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
329.77 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
545.11 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
244.32 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
iBio Inc Stock (IBIO) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-05-28 | Iniziato | Chardan Capital Markets | Buy |
| 2021-11-29 | Iniziato | JMP Securities | Mkt Outperform |
| 2021-01-22 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-06-26 | Iniziato | Alliance Global Partners | Buy |
iBio Inc Borsa (IBIO) Ultime notizie
iBio Extends Promissory Note Maturity to 2026 - TipRanks
Ibio nominates IBIO-610 as obesity development candidate - BioWorld MedTech
iBio initiates primate study for obesity antibody candidate IBIO-610 By Investing.com - Investing.com South Africa
iBio (IBIO) Begins Preclinical Study of New Antibody Candidate | - GuruFocus
iBio initiates primate study for obesity antibody candidate IBIO-610 - Investing.com
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment | IBIO Stock News - GuruFocus
iBio initiates non-human primate study of IBIO-610 - TipRanks
iBio Initiates Non-Human Primate Study of First-in-Class Activin E Antibody Following Positive Preclinical Data Demonstrating Prevention in Weight Regain After GLP-1 Treatment - The Manila Times
Breakthrough Obesity Drug Shows 77% Fat Reduction When Combined With GLP-1 Treatments - Stock Titan
iBio (IBIO) Plans to Offer 11.25 Million Shares of Common Stock - GuruFocus
Sector Update: Health Care - MarketScreener
IBio Files Prospectus for Resale of About 11.3 Million Shares - marketscreener.com
Plant-Based Vaccines Market Future Business Opportunities 2025-2032 | Medicago, Inc., IBIO, Icon Genetics GmbH - newstrail.com
iBio: University of Limerick programme to ‘shape the next generation’ of pharmaceutical manufacturing experts - University of Limerick
Merck & Co., Inc. (MRK): A Bull Case Theory - MSN
Plant-Based Vaccines Market Detailed In New Research Report - openPR.com
Insiders Who Purchased US$655.0k Of iBio Stock May Not Have Expected 23% Tumble - simplywall.st
Insider Buyers At iBio Likely Disappointed With 23% Slide - Yahoo Finance
Chardan Capital Has Pessimistic View of iBio FY2025 Earnings - Defense World
Chardan Capital Has Bearish Outlook for iBio FY2025 Earnings - Defense World
Would I Consider iBio Inc (NASDAQ: IBIO) Stock Any Time In The Future? - Stocksregister
Balance Sheet Dive: iBio Inc (IBIO)’s Debt-to-Equity and Long-Term Debt/Eq Ratios - DWinneX
iBio (IBIO) Rating Maintained at Buy by Chardan Capital | IBIO S - GuruFocus
iBio’s (IBIO) Buy Rating Reaffirmed at Chardan Capital - Defense World
iBio (NYSEMKT:IBIO) Shares Down 1.9% – Time to Sell? - Defense World
iBio announces new preclinical data for Activin E antibody - TipRanks
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Pri - GuruFocus
Chardan Capital Maintains Buy Rating for iBio (IBIO) with $5 Price Target | IBIO Stock News - GuruFocus
iBio (IBIO) Reports Promising Results from Activin E Antibody Study | IBIO Stock News - GuruFocus
iBio's First-in-Class Activin E Antibody Achieves >26% Fat Reduction Without Muscle Loss and Shows Synergy with GLP-1s in Preclinical Model - The Manila Times
iBio’s First-in-Class Activin E Antibody Achieves >26% Fat - GlobeNewswire
Revolutionary Obesity Treatment Achieves 77% Fat Reduction While Preserving Muscle Mass, Outperforms GLP-1s - Stock Titan
iBio, Inc. Reports Strong Q3 2025 Progress - TipRanks
iBio, Inc. (NYSE:IBIO) Shares Purchased by Geode Capital Management LLC - Defense World
iBio, Inc. (NYSEAMERICAN:IBIO) Short Interest Down 20.9% in April - Defense World
IBio Reports Fiscal Third Quarter 2025 Financial Results - marketscreener.com
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline - GuruFocus
iBio (IBIO) Secures Financial Growth and Advances Drug Pipeline | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results | IBIO Stock News - GuruFocus
iBio Reports Fiscal Third Quarter 2025 Financial Results - The Manila Times
iBio, Inc. Reports Q3 2025 Financial Results and Corporate Progress Following Nasdaq Listing - Nasdaq
iBio Reports Strong Pipeline Data and Nasdaq Uplisting as Q3 R&D Investment Doubles - Stock Titan
Take off with iBio Inc (IBIO): Get ready for trading - Sete News
iBio Raises $6.2 Million Through Warrant Inducement Transaction - The Manila Times
Analyzing iBio Inc (IBIO) After Recent Trading Activity - knoxdaily.com
iBio Raises $6.2 Million Through Warrant Inducement Transaction | IBIO Stock News - GuruFocus
Biotech Firm iBio Raises $6.2M in Fresh Capital: New Warrants Issued at $0.86 - Stock Titan
What to expect from iBio Inc’s (IBIO) current quarter earnings? - uspostnews.com
Teck Resources Ltd [TECK] Insider Activity: An Update for Investors - knoxdaily.com
iBio (NYSE:IBIO) Trading Up 14.3% – Should You Buy? - Defense World
An Overview of iBio Inc (NASDAQ: IBIO)’s Stock Performance and Outlook - Marketing Sentinel
iBio Inc Azioni (IBIO) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
iBio Inc Azioni (IBIO) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Brenner Martin | See Remarks |
Jan 10 '25 |
Buy |
2.72 |
9,191 |
25,000 |
18,316 |
| Banjak Marc | Chief Legal Officer |
Jan 10 '25 |
Buy |
2.72 |
9,191 |
25,000 |
11,066 |
| Arkowitz David | Director |
Jan 10 '25 |
Buy |
2.72 |
18,382 |
49,999 |
18,382 |
| Clark William D | Director |
Jan 10 '25 |
Buy |
2.72 |
1,838 |
4,999 |
1,838 |
| Parada Antonio Bernardino Guim | Director |
Jan 10 '25 |
Buy |
2.72 |
183,823 |
499,999 |
183,823 |
| Sender Gary | Director |
Jan 10 '25 |
Buy |
2.72 |
9,191 |
25,000 |
9,191 |
1.45%
0.86%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):